BRAF V600R-M-D are uncommon mutations, not included in the experimental protocols of BRAF selective inhibitors. We report the evaluation of correlations among different types of BRAF somatic mutations in melanoma and their management with BRAF inhibitors. 21 patients with BRAF mutated metastatic melanoma were enrolled in the protocol with BRAF inhibitors for compassionate use at the University of Modena. Hot spot V600E mutations were found in 19 patients. V600R mutation and double (V600E -V600M) mutation were identified in two melanomas. In one case, V600K mutation was found. Two screening failures were noted. Mean progression free survival at follow-up of to 8 weeks, was 7.6 months. Five patients had a very short follow-up and the experimental protocol is still ongoing, so we cannot provide complete follow-up data. However, all of them are still under treatment and disease progression free. An objective response with few side effects was observed in all patients. in vitro studies with the aim of testing drug sensitivity.

The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations / Ponti, Giovanni; Pellacani, Giovanni; Tomasi, Aldo; Gelsomino, F.; Spallanzani, A.; Depenni, R; Al Jalbout, S.; Simi, L.; Garagnani, L.; Borsari, S.; Conti, A.; Ruini, C.; Fontana, A.; Luppi, G.. - In: JOURNAL OF CLINICAL PATHOLOGY. - ISSN 0021-9746. - STAMPA. - 66:5(2013), pp. 441-445. [10.1136/jclinpath-2012-201345]

The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.

PONTI, Giovanni;PELLACANI, Giovanni;TOMASI, Aldo;F. Gelsomino;C. Ruini;
2013

Abstract

BRAF V600R-M-D are uncommon mutations, not included in the experimental protocols of BRAF selective inhibitors. We report the evaluation of correlations among different types of BRAF somatic mutations in melanoma and their management with BRAF inhibitors. 21 patients with BRAF mutated metastatic melanoma were enrolled in the protocol with BRAF inhibitors for compassionate use at the University of Modena. Hot spot V600E mutations were found in 19 patients. V600R mutation and double (V600E -V600M) mutation were identified in two melanomas. In one case, V600K mutation was found. Two screening failures were noted. Mean progression free survival at follow-up of to 8 weeks, was 7.6 months. Five patients had a very short follow-up and the experimental protocol is still ongoing, so we cannot provide complete follow-up data. However, all of them are still under treatment and disease progression free. An objective response with few side effects was observed in all patients. in vitro studies with the aim of testing drug sensitivity.
2013
66
5
441
445
The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations / Ponti, Giovanni; Pellacani, Giovanni; Tomasi, Aldo; Gelsomino, F.; Spallanzani, A.; Depenni, R; Al Jalbout, S.; Simi, L.; Garagnani, L.; Borsari, S.; Conti, A.; Ruini, C.; Fontana, A.; Luppi, G.. - In: JOURNAL OF CLINICAL PATHOLOGY. - ISSN 0021-9746. - STAMPA. - 66:5(2013), pp. 441-445. [10.1136/jclinpath-2012-201345]
Ponti, Giovanni; Pellacani, Giovanni; Tomasi, Aldo; Gelsomino, F.; Spallanzani, A.; Depenni, R; Al Jalbout, S.; Simi, L.; Garagnani, L.; Borsari, S.; ...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/925289
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 19
social impact